ClinicalTrials.gg
RecruitingNCT06207734Updated May 1, 2025

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

A Phase 2 interventional study of Continuation of CDK4/6 inhibitor Palbociclib and Discontinuation of CDK4/6 inhibitor Palbociclib in Breast Cancer, sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 13 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 196 under way, 81 of them phase 3. Breast Neoplasms · Germany.

Planned enrollment
409th of 580
120 · median 273
Started
2024
with 27 others
Phase 2
165 of 678
14 open now
Primary completion
2027-01
later than 71 of 195 live
Registered
601st of 678
by date

Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 409th largest by planned enrollment of the 580 interventional ones that give a count, is one of 28 that started in 2024, is one of 165 in phase 2, reaches primary completion later than 71 of the 195 other live ones, and was the 601st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 678 studies in Breast Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

This is a low-intervention, randomized, non-comparative, open-label, multicenter, prospective, phase II trial investigating discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control.

Read the detailed description

The primary objective is to evaluate long-term disease stabilization of CDK4/6 inhibitors discontinuation after a prolonged treatment period with continued endocrine therapy in breast cancer patients exhibiting at least stable disease after at least 12 months of combination treatment.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Metastatic HR positive, HER2 negative breast cancer
  • CDK4/6 inhibitors
  • Endocrine therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patient has given written
  2. Patient is ≥ 18 years of age at time of signing the written informed consent
  3. Patient has been diagnosed with confirmed adenocarcinoma of the breast
  4. Patient has documented histological or cytological confirmation of estrogen receptor positive (ER+) and negative (HER2-) disease
  5. Patient has no curative treatment option by surgery or radiotherapy
  6. Patient was treated with CDK4/6 inhibitor plus endocrine therapy for at least 12 months with disease control (complete remission, partial remission or stable disease) as judged by the treating physician before planned study treatment initiation
  7. Patient has a preserved performance status ( ≤ 2)
  8. Patient has adequate bone marrow, renal and hepatic function:

    1. > 9.0 g/dL
    2. judged as appropriate for study therapy by the investigator
    3. ≥ 100 x 109/L
    4. Calculated judged as appropriate for study therapy by the investigator
    5. (SGOT) / ALT (SGPT) and alkaline phosphatase ≤ 2.5x
    6. Serum albumin > 30 g/L
  9. Patients considered according to one of the following definition:

    1. Women \<50 years of age who are amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and whose levels of luteinizing hormone and follicle-stimulating hormone are in the post-menopausal institutional range
    2. Women ≥50 years of age who are amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago or had chemotherapy-induced menopause with last menses >1 year ago
    3. Artificially induced postmenopausal women (by Gonadotropin-releasing hormone [GnRH] analogs)
  10. must have a negative serum pregnancy test within 7 days prior to start of trial

Exclusion criteria

Exclusion Criteria:

  1. Patient has active (or history of) brain or
  2. Patient is pre- or perimenopausal. Patient is pregnant or breast feeding or planning to become pregnant within five times the half-life of the IMPs after the end of treatment.
  3. Patient has significant cardiovascular disease, such as cardiac disease ( Class II or greater), myocardial infarction or cerebrovascular accident within 6 months prior to initiation of study treatment, unstable arrhythmias, or unstable angina
  4. Patient has other concomitant or previous , except adequately treated in-situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of the skin, cancer in complete remission for > 5 years
  5. Patient has or shows to the existing treatment with CDK4/6 inhibitor plus endocrine therapy
  6. Patient shows evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results
  7. Patient participated in another clinical study with an medicinal product during the last 28 days before treatment initiation or 7 half-lives of previously used trial medication, whichever is longer or participate in such a study at the same time as this trial.

    Note: Participation in non-interventional clinical studies or registries is allowed.

  8. Any co-existing medical condition that in the investigator's judgement will substantially increase the risk associated with the patient's participation in the study.
  9. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities.
  10. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Control arm CDK4/6 continuation

    * Continuation of CDK4/6 inhibitor treatment * Continuation of endocrine treatment

    Drug: Continuation of CDK4/6 inhibitor Palbociclib · Drug: Continuation of CDK4/6 inhibitor -Palbociclib · Drug: Continuation of CDK4/6 inhibitor Abemaciclib

  • Experimental
    Experimental arm CDK4/6 inhibitor discontinuation

    * Discontinuation of CDK4/6 inhibitor treatment * Continuation of endocrine treatment

    Drug: Discontinuation of CDK4/6 inhibitor Palbociclib · Drug: Discontinuation of CDK4/6 inhibitor -Palbociclib · Drug: Discontinuation of CDK4/6 inhibitor Abemaciclib

Interventions

  • DrugContinuation of CDK4/6 inhibitor Palbociclib

    Continuation of CDK4/6 inhibitor Palbociclib

    Also known as: Study treatment

  • DrugDiscontinuation of CDK4/6 inhibitor Palbociclib

    Discontinuation of CDK4/6 inhibitor Palbociclib

    Also known as: Study treatment

  • DrugContinuation of CDK4/6 inhibitor -Palbociclib

    Continuation of CDK4/6 inhibitor -Palbociclib

    Also known as: Study treatment

  • DrugDiscontinuation of CDK4/6 inhibitor -Palbociclib

    Discontinuation of CDK4/6 inhibitor -Palbociclib

    Also known as: Study treatment

  • DrugContinuation of CDK4/6 inhibitor Abemaciclib

    Continuation of CDK4/6 inhibitor Abemaciclib

    Also known as: Study treatment

  • DrugDiscontinuation of CDK4/6 inhibitor Abemaciclib

    Discontinuation of CDK4/6 inhibitor Abemaciclib

    Also known as: Study treatment

This study also gives PalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-free survival rate 12 months after randomization (PFS@12_stopping)

    Proportion of patients alive and without progression according to radiologic imaging assessment

    Time frame: 12 months

Secondary outcomes

  1. Progression-free survival (PFS)

    Time from randomization until progress

    Time frame: 54 months

  2. Time to treatment failure (TTF)

    Time from randomization to end of treatment because of patient's wish, investigator's decision, toxicity, or progression

    Time frame: 54 months

  3. Progression-free survival (PFS2)

    Time from re-treatment with CDK4/6 inhibitors to clinical disease progression or death from any cause

    Time frame: 54 months

  4. Time to treatment failure (TTF2)

    Time to end of treatment because of patient's wish, investigator's decision, toxicity, or clinical progression after re-treatment with CDK4/6 inhibitors

    Time frame: 54 months

  5. Time to first use of chemotherapy

    Time to first use of chemotherapy after progression on combined endocrine/CDK4/6 inhibitor treatment

    Time frame: 54 months

  6. Quality of life (QoL) EORTC QLQ-C30

    QoLassessed with the QoL questionnaire EORTC QLQ-C30

    Time frame: 54 months

  7. Quality of life (QoL) EORTC QLQ-BR23

    QoLassessed with the QoL questionnaire EORTC QLQ-BR23

    Time frame: 54 months

  8. Safety (rate of adverse events)

    Type, incidence and severity of adverse events (AEs) and serious adverse events (SAEs) graded according to NCI CTCAE v5.0

    Time frame: 54 months

07

Study locations

10 of 13 sites recruiting
  • Charité Berlin
    Berlin, Germany
    Recruiting
  • Hämatologische Onkologische Praxis im Medicum
    Bremen, Germany
    Recruiting
  • St. Johannes Hospital Dortmund
    Dortmund, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Praxis und Tagesklinik
    Friedrichshafen, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Hausärztliche und Onkologische Gemeinschaftspraxis
    Gerlingen, Germany
    Recruiting
  • Onkologische GP Gütersloh
    Gütersloh, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Hämatologisch-Onkologische Praxis Altona
    Hamburg, Germany
    Recruiting
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, Germany
    Recruiting
  • MVZ für Hämatologie und Onkologie der MVZ Mülheim GmbH
    Mülheim, Germany
    Recruiting
  • MVZ für Hämatologie und Onkologie
    Ravensburg, 88212, Germany
    Recruiting
    • Thomas Decker, Prof. · Contact
  • Krankenhaus Barmherzige Brüder Regensburg
    Regensburg, Germany
    Recruiting
  • Onkologisch-Gastroenterologische Schwerpunktpraxis Innere Medizin GbR
    Singen, 78224, Germany
    Recruiting
  • Onkologiezentrum Soest-Iserlohn
    Soest, 59494, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — No IPD will be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 35 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 35 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2024
First posted
Jan 17, 2024
StartActual
Jan 17, 2024
Primary completionEst.
Jan 10, 2027
CompletionEst.
Jul 10, 2028
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06207734
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Responsible party
Sponsor
First posted
Jan 17, 2024
Start date
Jan 17, 2024
Primary completion
Jan 10, 2027 (estimated)
Completion
Jul 10, 2028 (estimated)
Last update
May 1, 2025

Study contacts

Thomas Decker, Prof.
Contact
Thomas.Decker@onkonet.eu
+49 751 366197 ext. 0
Regina Eickhoff, Dr.
Contact
eickhoff.regina@ikf-khnw.de
+49 69 / 5899 787 ext. 33
Salah-Eddin Al-Batran, Prof.
study director · Frankfurter Institut für Klinische Krebsforschung IKF GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Palbociclib · Abemaciclib

Start the discussion